ArticleThe American journal of cardiology2009
Treating children with idiopathic dilated cardiomyopathy (from the Pediatric Cardiomyopathy Registry).
Article in The American journal of cardiology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 60 citations in OpenAlex.
- Extrapolation of Adult Evidence to Pediatric Practice: Bridging the Gap in Pediatric Heart Failure Pharmacotherapy.Children (Basel, Switzerland) · 2026Review
- Article
- Pediatric dilated cardiomyopathy: a review of current clinical approaches and pathogenesis.Frontiers in pediatrics · 2024Review
- Compound Heterozygosity for Late-Onset Cardiomyopathy-Causative ALPK3 Coding Variant and Novel Intronic Variant Cause Infantile Hypertrophic Cardiomyopathy.Journal of cardiovascular translational research · 2023Article
- Parameters affecting outcome of paediatric cardiomyopathies in the intensive care unit: experience of an Egyptian tertiary centre over 7 years.The Libyan journal of medicine · 2020Article
- Pediatric heart failure therapy: why β1-receptor blocker, tissue ACE-I and mineralocorticoid-receptor-blocker?Translational pediatrics · 2019Review
- Survival Without Cardiac Transplantation Among Children With Dilated Cardiomyopathy.Journal of the American College of Cardiology · 2017Observational
- Childhood Cardiomyopathies: A Study in Tertiary Care Hospital in Upper Egypt.Electronic physician · 2016Article
- Natural History of Dilated Cardiomyopathy in Children.Journal of the American Heart Association · 2016Article
- Dysregulation of cardiolipin biosynthesis in pediatric heart failure.Journal of molecular and cellular cardiology · 2014Article
- Massive Cardiomegaly due to Dilated Cardiomyopathy Causing Bronchial Obstruction in an Infant.Journal of cardiovascular ultrasound · 2014Article
- Pediatric cardiomyopathies: causes, epidemiology, clinical course, preventive strategies and therapies.Future cardiology · 2013Review
- Stem cell therapy for pediatric dilated cardiomyopathy.Current cardiology reports · 2013Review
- Cardiomyopathies in children.Korean journal of pediatrics · 2013Article
- Heart rate variability abnormalities in young patients with dilated cardiomyopathy.Pediatric cardiology · 2012Article
- Early predictors of survival to and after heart transplantation in children with dilated cardiomyopathy.Circulation · 2012Article
- Therapeutic role of mobilized bone marrow cells in children with nonischemic dilated cardiomyopathy.ISRN pediatrics · 2012Article
- The pediatric cardiomyopathy registry and heart failure: key results from the first 15 years.Heart failure clinics · 2010Review
- Cardiomyopathies: Treating pediatric DCM--great expectations unfulfilled.Nature reviews. Cardiology · 2010Article
- Role of β-blocker therapy in pediatric heart failure.Pediatric health · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
Abstract
In 40% of children with symptomatic idiopathic dilated cardiomyopathy (IDC), medical therapy fails within 2 years of diagnosis. Strong evidence-based therapies are not available for these children, and how evidence-based therapies for adults with IDC should be applied to children is unclear. Using data from the National Heart, Lung, and Blood Institute's Pediatric Cardiomyopathy Registry, we compared practice patterns of initial therapies for children with IDC diagnosed from 1990 to 1995 (n = 350) and from 2000 to 2006 (n = 219). At diagnosis, 73% had symptomatic heart failure (HF), and 7% had > or =1 family member with IDC. Anti-HF medications were most commonly prescribed initially. Anti-HF medication use was similar across the 2 periods (84% and 87%, respectively), as was angiotensin-converting enzyme inhibitor use (66% and 70%, respectively). These medications were used more commonly in children with greater left ventricular dilation and poorer left ventricular fractional shortening and functional class (p <0.001). Beta-blocker use was 4% to 18% over the 2 periods. Treatments for pediatric IDC have changed little over the previous 25 years. Anti-HF medications remain the most common treatment, and they are often given to children with asymptomatic left ventricular dysfunction. Children with asymptomatic left ventricular dysfunction are often not offered angiotensin-converting enzyme inhibitors without echocardiographic evidence of advanced disease. In conclusion, therapeutic clinical trials are strongly indicated because practice variation is substantial and medical outcomes in these children have not improved in the previous several decades.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.